NCT06095973View on ClinicalTrials.gov

Dose-Escalation, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GB-6002 Local Infiltration in Healthy Male Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 24, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions

Pain, Postoperative

Interventions

DRUG

GB-6002

Depending on the cohort, volume will be varied to administer.

DRUG

Placebo

Depending on the cohort, volume will be varied to administer. Volume to be matched with the active investigational drug in the respective cohort.

DRUG

Naropin injection

Single dose of Naropin s.c. injection.

Trial Locations (1)

Unknown

Seoul National University Bundang Hospital, Seongnam-si

All Listed Sponsors

lead

G2GBio, Inc.

INDUSTRY

NCT06095973 - Dose-Escalation, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GB-6002 Local Infiltration in Healthy Male Adults | Biotech Hunter | Biotech Hunter